← Back to Search

Procedure

A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement

Minneapolis, MN
N/A
Waitlist Available
Led By Sean Elliott, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

We propose a randomized non-blinded comparison of standard vs. transcorporal approach for placement of an artificial urinary sphincter in male patients with stress urinary incontinence after radiation and radical prostatectomy for prostate cancer. In the United States, the artificial urinary sphincter (AUS), manufactured by American Medical Systems, is the gold standard surgical treatment for stress urinary incontinence (SUI) in men. The cuff, which is the portion of the device that encircles and occludes the urethra, is typically placed directly around the urethra (i.e., "standard" placement). The cuff can erode into the urethra. Transcorporal placement has been introduced as a method to reduce the risk of erosion. Transcorporal placement involves tunneling the cuff through the erectile bodies so as to protect the dorsal aspect of the urethra. This approach has never been compared to standard placement in a randomized fashion. In our randomized trial, no additional procedures beyond the normal care protocol will be required of the patients. We will conduct the study through our established, IRB-approved multi-institutional network of surgeons. Success will be assessed via objective and subjective methods; complications will be tallied in a standardized fashion. Outcomes will be measured at two years.

See full description
Eligible Conditions
  • Stress Incontinence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AUS Removal/Revision
Secondary study objectives
Incontinence
Incontinence Quality of Life
Sexual Function
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Transcorporal AUSExperimental Treatment1 Intervention
The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
Group II: Standard AUSActive Control1 Intervention
The artificial urinary sphincter is placed in the standard fashion.

Find a Location

Closest Location:University of Minnesota Medical Center· Minneapolis, MN

Who is running the clinical trial?

University of IowaOTHER
483 Previous Clinical Trials
933,481 Total Patients Enrolled
University of KansasOTHER
156 Previous Clinical Trials
331,784 Total Patients Enrolled
Loyola University ChicagoOTHER
22 Previous Clinical Trials
13,140 Total Patients Enrolled
Lahey ClinicOTHER
72 Previous Clinical Trials
245,058 Total Patients Enrolled
University of California, San FranciscoOTHER
2,623 Previous Clinical Trials
19,027,153 Total Patients Enrolled
University of WashingtonOTHER
1,850 Previous Clinical Trials
2,022,518 Total Patients Enrolled
New York UniversityOTHER
245 Previous Clinical Trials
228,435 Total Patients Enrolled
University of California, San DiegoOTHER
1,208 Previous Clinical Trials
1,591,747 Total Patients Enrolled
University of UtahOTHER
1,159 Previous Clinical Trials
1,639,276 Total Patients Enrolled
Ohio State UniversityOTHER
878 Previous Clinical Trials
659,001 Total Patients Enrolled
~0 spots leftby Mar 2026